Stock Scorecard
Stock Summary for Evolus Inc (EOLS) - $6.70 as of 10/24/2025 7:26:35 PM EST
Total Score
8 out of 30
Safety Score
29 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for EOLS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for EOLS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for EOLS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for EOLS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for EOLS (29 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 7 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for EOLS
Financial Details for EOLS
Company Overview |
|
|---|---|
| Ticker | EOLS |
| Company Name | Evolus Inc |
| Country | USA |
| Description | Evolus, Inc. is a dynamic aesthetic medical company based in Newport Beach, California, renowned for its innovative beauty solutions tailored for healthcare providers and their patients. The company’s flagship product, Jeuveau, is a neurotoxin uniquely developed for the cosmetic market, demonstrating Evolus's commitment to quality and efficacy in enhancing aesthetic results. As a pivotal entity within the expanding aesthetic industry, Evolus is focused on broadening its portfolio and penetrating new markets, positioning itself as a forward-thinking leader in advanced beauty solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/11/2025 |
Stock Price History |
|
| Last Day Price | 6.70 |
| Price 4 Years Ago | 6.51 |
| Last Day Price Updated | 10/24/2025 7:26:35 PM EST |
| Last Day Volume | 357,933 |
| Average Daily Volume | 991,214 |
| 52-Week High | 17.44 |
| 52-Week Low | 5.71 |
| Last Price to 52 Week Low | 17.34% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 90.61 |
| Sector PE | 41.12 |
| 5-Year Average PE | -17.30 |
| Free Cash Flow Ratio | 7.05 |
| Industry Free Cash Flow Ratio | 13.66 |
| Sector Free Cash Flow Ratio | 31.25 |
| Current Ratio Most Recent Quarter | 2.27 |
| Total Cash Per Share | 0.95 |
| Book Value Per Share Most Recent Quarter | -0.29 |
| Price to Book Ratio | 53.71 |
| Industry Price to Book Ratio | 11.41 |
| Sector Price to Book Ratio | 32.29 |
| Price to Sales Ratio Twelve Trailing Months | 1.59 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.78 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.43 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 64,685,000 |
| Market Capitalization | 433,389,500 |
| Institutional Ownership | 90.43% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 18.26% |
| Reported EPS 12 Trailing Months | -0.97 |
| Reported EPS Past Year | -0.44 |
| Reported EPS Prior Year | -0.28 |
| Net Income Twelve Trailing Months | -61,995,000 |
| Net Income Past Year | -50,420,000 |
| Net Income Prior Year | -61,685,000 |
| Quarterly Revenue Growth YOY | 3.70% |
| 5-Year Revenue Growth | 50.12% |
| Operating Margin Twelve Trailing Months | -20.40% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 61,738,000 |
| Total Cash Past Year | 86,952,000 |
| Total Cash Prior Year | 62,838,000 |
| Net Cash Position Most Recent Quarter | -83,737,000 |
| Net Cash Position Past Year | -34,554,000 |
| Long Term Debt Past Year | 121,506,000 |
| Long Term Debt Prior Year | 120,359,000 |
| Total Debt Most Recent Quarter | 145,475,000 |
| Equity to Debt Ratio Past Year | 0.04 |
| Equity to Debt Ratio Most Recent Quarter | -0.15 |
| Total Stockholder Equity Past Year | 5,522,000 |
| Total Stockholder Equity Prior Year | -20,689,000 |
| Total Stockholder Equity Most Recent Quarter | -18,652,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -46,302,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.72 |
| Free Cash Flow Past Year | -19,471,000 |
| Free Cash Flow Prior Year | -35,635,000 |
Options |
|
| Put/Call Ratio | 6.25 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.11 |
| MACD Signal | -0.19 |
| 20-Day Bollinger Lower Band | 5.02 |
| 20-Day Bollinger Middle Band | 7.79 |
| 20-Day Bollinger Upper Band | 10.57 |
| Beta | 1.04 |
| RSI | 53.41 |
| 50-Day SMA | 10.42 |
| 150-Day SMA | 10.74 |
| 200-Day SMA | 10.49 |
System |
|
| Modified | 10/22/2025 10:51:42 PM EST |